Vinblastine and Methotrexate for Desmoid Fibromatosis in Children: Results of a Pediatric Oncology Group Phase II Trial
Authors:
- Stephen X. SkapekSSStephen X. Skapek
- William S. FergusonWFWilliam S. Ferguson
- Linda GranowetterLGLinda Granowetter
- Meenakshi DevidasMDMeenakshi Devidas
- Antonio R. Perez-AtaydeAPAntonio R. Perez-Atayde
- Louis P. DehnerLDLouis P. Dehner
- Fredric A. HofferFHFredric A. Hoffer
- Roseanne SpeightsRSRoseanne Speights
- Mark C. GebhardtMGMark C. Gebhardt
- Gary V. DahlGDGary V. Dahl
- Holcombe E. GrierHGHolcombe E. Grier
- 10 February 2007
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (5) , 501-506
Abstract
Purpose: To determine the efficacy and safety of using vinblastine (Vbl) and methotrexate (Mtx) in children with desmoid-type fibromatosis that is recurrent or not amenable to treatment with radiation or surgery. Patients and Methods: A phase II study was conducted within the Pediatric Oncology Group. Patients were treated using Vbl (5 mg/m2/dose) and Mtx (30 mg/m2/dose), both administered by intravenous injection weekly for 26 weeks and every other week for an additional 26 weeks. Response was assessed by bidimensional measurements of tumor on axial imaging (magnetic resonance imaging or computed tomography). Results: Over 35 months, 28 patients were enrolled; 27 were eligible, and 26 were assessable for response. A measurable response was documented in eight patients (31%), and 10 patients had stable disease documented as the best response to treatment. Eighteen patients had disease progression at a median time of 9.1 months. Eight patients remain free of disease progression at a median of 43.4 months from study entry. Nine patients reported no to moderate toxicity. Neutropenia was the most common toxicity (n = 22) and the most common grade 4 toxicity (n = 5). Anemia, nausea, vomiting, and elevations in hepatic transaminases were also common and were reversible with interruption of chemotherapy. Conclusion: Vbl and Mtx are well tolerated in children with desmoid-type fibromatosis. Furthermore, this combination can promote tumor regression or block tumor growth in most children.Keywords
This publication has 35 references indexed in Scilit:
- Successful Chemotherapeutic Modality of Doxorubicin Plus Dacarbazine for the Treatment of Desmoid Tumors in Association With Familial Adenomatous PolyposisJournal of Clinical Oncology, 2006
- Response of extraabdominal desmoid tumors to therapy with imatinib mesylateCancer, 2002
- Fibromatoses in childhood: The desmoid/fibromatosis complex*Medical and Pediatric Oncology, 2001
- Surgical management of intra-abdominal desmoid tumoursBritish Journal of Surgery, 2000
- Noncytotoxic drug therapy for intra-abdominal desmoid tumor in patients with familial adenomatous polyposisDiseases of the Colon & Rectum, 1992
- Low-dose chemotherapy of desmoid tumorsCancer, 1989
- The use of indomethacin, sulindac, and tamoxifen for the treatment of desmoid tumors associated with familial polyposisCancer, 1987
- Confidence Intervals for a Binomial Parameter Based on Multistage TestsBiometrics, 1987
- Estrogen and antiestrogen binding sites in desmoid tumorsEuropean Journal of Cancer and Clinical Oncology, 1986
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958